CA2989247C - Vegfr-2 targeting dna vaccine for combination therapy - Google Patents

Vegfr-2 targeting dna vaccine for combination therapy Download PDF

Info

Publication number
CA2989247C
CA2989247C CA2989247A CA2989247A CA2989247C CA 2989247 C CA2989247 C CA 2989247C CA 2989247 A CA2989247 A CA 2989247A CA 2989247 A CA2989247 A CA 2989247A CA 2989247 C CA2989247 C CA 2989247C
Authority
CA
Canada
Prior art keywords
salmonella
attenuated strain
protein
seq
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2989247A
Other languages
English (en)
French (fr)
Other versions
CA2989247A1 (en
Inventor
Heinz Lubenau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaximm AG
Original Assignee
Vaximm AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaximm AG filed Critical Vaximm AG
Publication of CA2989247A1 publication Critical patent/CA2989247A1/en
Application granted granted Critical
Publication of CA2989247C publication Critical patent/CA2989247C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA2989247A 2015-06-18 2016-06-16 Vegfr-2 targeting dna vaccine for combination therapy Active CA2989247C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15001803 2015-06-18
EP15001803.4 2015-06-18
PCT/EP2016/001004 WO2016202459A1 (en) 2015-06-18 2016-06-16 Vegfr-2 targeting dna vaccine for combination therapy

Publications (2)

Publication Number Publication Date
CA2989247A1 CA2989247A1 (en) 2016-12-22
CA2989247C true CA2989247C (en) 2023-10-17

Family

ID=53476620

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2989247A Active CA2989247C (en) 2015-06-18 2016-06-16 Vegfr-2 targeting dna vaccine for combination therapy

Country Status (19)

Country Link
US (2) US10905752B2 (https=)
EP (2) EP3310379B1 (https=)
JP (1) JP6947649B2 (https=)
KR (2) KR20250024816A (https=)
CN (1) CN107995868B (https=)
AU (1) AU2016278588B2 (https=)
BR (1) BR112017027378A2 (https=)
CA (1) CA2989247C (https=)
DK (1) DK3310379T3 (https=)
ES (2) ES2760699T3 (https=)
HU (1) HUE046631T2 (https=)
IL (1) IL256076A (https=)
LT (1) LT3310379T (https=)
MX (1) MX2017016183A (https=)
PL (2) PL3626262T3 (https=)
RU (1) RU2018101722A (https=)
SI (1) SI3310379T1 (https=)
WO (1) WO2016202459A1 (https=)
ZA (1) ZA201708439B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3041375A1 (en) * 2016-11-04 2018-05-11 Vaximm Ag Wt1 targeting dna vaccine for combination therapy
WO2018149982A1 (en) * 2017-02-17 2018-08-23 Vaximm Ag Novel vegfr-2 targeting immunotherapy approach
JP7247097B2 (ja) * 2017-03-17 2023-03-28 バクシム アクチェンゲゼルシャフト がん免疫療法のための新規ｐｄ－ｌ１標的ｄｎａワクチン
JP7598315B2 (ja) * 2018-09-05 2024-12-11 エンエーセー オンコイミュニティ アクスイェ セルスカプ 併用療法用ｄｎａワクチンを標的とするネオアンチゲン
US20230121528A1 (en) * 2020-01-13 2023-04-20 Vaximm Ag Salmonella-based dna vaccines in combination with an antibiotic
EP3922255A1 (en) * 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094410B2 (en) 2002-03-02 2006-08-22 The Scripps Research Institute DNA vaccine against proliferating endothelial cells and methods of use thereof
NO337687B1 (no) 2011-07-08 2016-06-06 Norsk Elektro Optikk As Hyperspektralt kamera og metode for å ta opp hyperspektrale data
CA2853656C (en) 2011-12-22 2020-12-29 Vaximm Ag Method of producing high yield attenuated salmonella strains
JP6325534B2 (ja) * 2012-07-05 2018-05-16 バクシム アクチェンゲゼルシャフト 膵臓癌患者用ｄｎａワクチン
PL2897620T3 (pl) * 2012-09-21 2020-11-02 Intensity Therapeutics, Inc Sposób leczenia nowotworu złośliwego
US9974845B2 (en) * 2013-02-22 2018-05-22 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
MX364922B (es) 2013-04-25 2019-05-14 Vaximm Ag Vacuna de adn que dirige wt-1 novedosa para inmunoterapia contra cáncer.
SI3082850T1 (sl) * 2013-12-18 2020-01-31 Vaximm Gmbh DNA cepivo, ki cilja MSLN za imunoterapijo raka
WO2018149982A1 (en) * 2017-02-17 2018-08-23 Vaximm Ag Novel vegfr-2 targeting immunotherapy approach
JP7247097B2 (ja) * 2017-03-17 2023-03-28 バクシム アクチェンゲゼルシャフト がん免疫療法のための新規ｐｄ－ｌ１標的ｄｎａワクチン

Also Published As

Publication number Publication date
ZA201708439B (en) 2021-05-26
BR112017027378A2 (pt) 2018-08-28
EP3626262A1 (en) 2020-03-25
US20180250345A1 (en) 2018-09-06
IL256076A (en) 2018-01-31
MX2017016183A (es) 2018-06-19
EP3626262C0 (en) 2024-10-23
SI3310379T1 (sl) 2020-02-28
JP2018517419A (ja) 2018-07-05
EP3310379A1 (en) 2018-04-25
RU2018101722A (ru) 2019-07-18
DK3310379T3 (da) 2019-12-16
ES2760699T3 (es) 2020-05-14
WO2016202459A1 (en) 2016-12-22
ES2994561T3 (en) 2025-01-27
HUE046631T2 (hu) 2020-03-30
PL3626262T3 (pl) 2025-02-17
CA2989247A1 (en) 2016-12-22
CN107995868B (zh) 2021-07-13
EP3626262B1 (en) 2024-10-23
RU2018101722A3 (https=) 2019-12-10
EP3310379B1 (en) 2019-11-06
LT3310379T (lt) 2019-12-27
AU2016278588A1 (en) 2017-12-21
AU2016278588B2 (en) 2022-03-31
CN107995868A (zh) 2018-05-04
US20210077605A1 (en) 2021-03-18
JP6947649B2 (ja) 2021-10-13
US10905752B2 (en) 2021-02-02
HK1252435A1 (en) 2019-05-24
KR20180037948A (ko) 2018-04-13
PL3310379T3 (pl) 2020-03-31
KR20250024816A (ko) 2025-02-19

Similar Documents

Publication Publication Date Title
US20210077605A1 (en) Vegfr-2 targeting dna vaccine for combination therapy
US20220273782A1 (en) Novel PD-L1 Targeting DNA Vaccine for Cancer Immunotherapy
JP2023160838A (ja) 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ
US20230158133A1 (en) Wt1 targeting dna vaccine for combination therapy
HK40026195B (en) Vegfr-2 targeting dna vaccine for combination therapy
HK40026195A (en) Vegfr-2 targeting dna vaccine for combination therapy
HK1252435B (en) Vegfr-2 targeting dna vaccine for combination therapy
US20230121528A1 (en) Salmonella-based dna vaccines in combination with an antibiotic

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210527

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251202

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251209

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260316